Sustained improvement of cognition and global function in patients with moderately severe Alzheimer’s disease:a double-blind, placebo-controlled study with the neurotrophic agent Cerebrolysin®

  • E. Ruether
  • X. A. Alvarez
  • M. Rainer
  • H. Moessler
Part of the Journal of Neural Transmission. Supplementa book series (NEURAL SUPPL, volume 62)


Background: In a recent study, Cerebrolysin®(Cere),a compound with neurotrophic activity,has been shown to be effective in the treatment of mild to moderate Alzheimer’s disease (AD).A subgroup analysis of this double-blind,placebo-controlled study was performed to assess the effects of Cere in cases with more advanced forms of AD.

Patienst and methods: Patients received infusions of 30ml Cere or placebo with neurotrophic activity, has been shown to be effective in the treatment of mild to moderate Alzheimer’s disease (AD). A subgroup analysis of this double-blind, placebo-controlled study was performed to assess the effects of Cere in cases with more advanced forms of AD.

Results: The responder rate of the Cere group was 65% on the CGI, compared to 24.5% in the placebo group (p < 0.004). In the ADAS-cog, a score difference of 4.1 points in favour of Cere was observed (p < 0.0001). Notably, improvements were largely maintained in the Cere group up to the week 28 visit.

Conclusion: The data clearly demonstrate the efficacy of Cere treatment in moderate to severe forms of AD wth sustained treatment effects on cognition and global function even after discontinuation of treatment.


Global Function Responder Rate Clinical Global Impression Responder Analysis Nootropic Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Akai F, Hiruma S, Sato T et al (1992) Neurotrophic factor-like effect of FPF1070 on septal cholinergic neurons after transections of fimbria-fornix in the rat brain.Ristol Histopathol 7: 213–221Google Scholar
  2. Bae C-Y, Cho C-Y, Cho K, Oh BH, Choi KG, Lee HS, Jung SP, Kim DH, Lee S, Choi G-D, Cho H, Lee H (2000) A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer’s disease.JAGS 48: 1566–1571Google Scholar
  3. Erzigkeit H (1989) The SKT - a short cognitive performance test as an instrument for the assessment of clinical efficacy of cognitive enhancers.In: Bergner W, Reisberg B (eds) Diagnosis and treatment of senile dementia.Springer,Berlin Heidelberg New York TokyoGoogle Scholar
  4. Francis-Turner L, Valouskova V (1996) Nerve growth factor and nootropic drug Cerebrolysin but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbria-fornix transection: short-term study.Neurosci Lett 202: 1–4CrossRefGoogle Scholar
  5. Folstein MF,Folstein SE,McHugh PR (1975) “Mini-Mental State”.A practical method for grading the cognitive state of patients for the clinician.J Psychiatr Res 12: 189–198PubMedCrossRefGoogle Scholar
  6. Gauthier S (1999) Acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease.Exp Opin Exp Drugs 8: 1511–1520CrossRefGoogle Scholar
  7. Gray J, Gauthier S (1999) Stabilization approaches to Alzheimer’s disease.In: Gauthier S (ed) Clinical diagnosis and management of Alzheimer’s disease,2nd ed.Martin Dunitz, London, p 269Google Scholar
  8. Gschanes A, Valouskova V, Windisch M (1997) Ameliorative influence of a nootropic drug on motor activity of rats after bilateral carotid artery occlusion.J Neural Transm 104: 1319–1327PubMedCrossRefGoogle Scholar
  9. Guy W (1976) ECDEU Assessment for Psychopharmacology, rev edn. National Institute of Mental Health,Rockville,MDGoogle Scholar
  10. Masliah E, Armasolo F, Veinbergs I, Mallory M, Samuel W (1999) Cerebrolysin ameliorates performance deficits, and neuronal damage in apolipoprotein E-deficient mice.Pharmacol Biochem Behav 62 (2): 239–245PubMedCrossRefGoogle Scholar
  11. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer’s Disease.Neurology 34: 39–11CrossRefGoogle Scholar
  12. Montgomery SA, Asberg M (1979) A new depression rating scale designed to be sensitive to change.Br J Psychiatry 134: 382–389PubMedCrossRefGoogle Scholar
  13. Oswald W, Fleischmann U (1980) Das Nuernberger-Alters-Inventar (NAI):Kurzbeschreibung, Testanleitung, Normwerte, Testmaterial.Institutspublikation,StuttgartGoogle Scholar
  14. Panisset M, Gauthier S, Moessler H et al (2002) Cerebrolysin in Alzheimer’s disease:a randomized, double-blind, placebo-controlled trial with a neurotrophic agent.J Neural Transm 109: 1089–1104PubMedCrossRefGoogle Scholar
  15. Reinprecht I, Gschanes A, Windisch M, Fachbach G (1999) Two peptidergic drugs increase the synaptophysin immunoreactivity in brains of 24-month-old-rats.Histochem J 31: 395–401PubMedCrossRefGoogle Scholar
  16. Rockenstein E, Mallory M, Mante M, Sagara Y, Windisch M, Moessler H, Masliah E (2000) Effects of Cerebrolysin in human APP transgenic animal models of Alzheimer’s disease.Neurobiol Aging 21: 168CrossRefGoogle Scholar
  17. Rosen WG, Terry RD, Fuld P, Katzman R, Peck A (1980) Pathological verification of Ischemia Score in differentiation of dementias.Ann Neurol 7: 486–488PubMedCrossRefGoogle Scholar
  18. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer’s disease.Am J Psychiatry 141: 1356–1364PubMedGoogle Scholar
  19. Ruether E, Ritter R, Apecechea M, Freytag S, Windisch M (1994) Efficacy of the peptidergic nootropic drug Cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT).Pharmacopsychiatry 27 (1): 32–40CrossRefGoogle Scholar
  20. Ruether E, Ritter R, Apecechea M, Freytag S, Gmeinbauer R, Windisch M (2000) Sustained improvements in patients with dementia of Alzheimer’s type (DAT) 6 months after termination of Cerebrolysin therapy.J Neural Transm 107:815–829CrossRefGoogle Scholar
  21. Ruether E, Husmann R, Kinzler E et al (2001) A 28 week, double-blind, placebocontrolled study with Cerebrolysin in patients with mild to moderate Alzheimer’s disease.Int Clin Pharmaco l16: 253–263Google Scholar
  22. Satou T, Imano M, Akai F, Hashimoto S, Hoh T, Fujimoto M (1993) Morphological observation of effects of Cerebrolysin on cultured neuronal cells.Adv Biosci 87: 195–196Google Scholar
  23. Satou T, Hoh T, Fujimoto M, Hashimoto S (1994) Neurotrophic-like effects ofFPF-1070 on cultured neurons from chick embryonic dorsal root ganglia.Jpn Pharmacol Ther 22: 205–212Google Scholar
  24. Tatebayashi (2000) The peptidergic antidementia drug Cerebrolysin increases neurogenesis in the adult rat dentate gyrus and improves spatial learning and memory. Neurobiol Aging 21: 42CrossRefGoogle Scholar
  25. Valouskova V, Francis-Turner L (1998) Can Cerebrolysin influence chronic deterioration of spatial learning and memory? J Neural Transm 52 [Suppl]: 343–349CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2002

Authors and Affiliations

  • E. Ruether
    • 1
  • X. A. Alvarez
    • 2
  • M. Rainer
    • 3
  • H. Moessler
    • 4
  1. 1.Klinik und Poliklinik für PsychiatrieGeorg-August-UniversitätGöttingenFederal Republic of Germany
  2. 2.EuroEspes Biomedical Research CentreLa CorunaSpain
  3. 3.Psychiatry DepartmentHospital SMZ-OstVienna
  4. 4.EBEWE Pharmaceuticals LtdUnterachAustria

Personalised recommendations